Current status of irinotecan in lung cancer.

Abstract

Survival in lung cancer patients has not improved over the past 2 decades. Irinotecan (Camptosar, CPT-11), a semisynthetic analog of the quinoline-based alkaloid camptothecin, is one of several new drugs that have demonstrated promising activity in the treatment of lung cancer in recent years. This article gives a brief overview of the mechanism, development history, and current uses of this agent.

• Authors: M Fukuoka
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 15 Issue 1 Suppl 1 Pg. 6-7 (Jan 2001) ISSN: 0890-9091 [Print] United States
• PMID: 11221022 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents, Phytogenic
• Irinotecan
• Camptothecin

Topics

• Antineoplastic Agents, Phytogenic (therapeutic use)
• Camptothecin (analogs & derivatives, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality)
• Carcinoma, Small Cell (drug therapy, mortality)
• Clinical Trials as Topic
• Humans
• Irinotecan
• Lung Neoplasms (drug therapy, mortality)
• Survival Rate